candesartan cilexetil has been researched along with Albuminuria in 15 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 9.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
| "These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension." | 9.11 | Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. ( Hasebe, N; Kikuchi, K, 2005) |
| "CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 5.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
| "These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension." | 5.11 | Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. ( Hasebe, N; Kikuchi, K, 2005) |
| "Fifty-two patients with type 2 diabetes with normo- and microalbuminuria participated in this study." | 2.71 | Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. ( Adachi, M; Hirano, T; Ikejiri, R; Murayama, S; Okada, K; Sakaue, T, 2003) |
| "Many patients with diabetic nephropathy (DN) have levels of albuminuria > 1 g/day and blood pressure >135/85 mmHg, despite antihypertensive combination therapy, including recommended doses of ACE inhibitors, e." | 2.70 | Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. ( Christensen, PK; Jensen, BR; Parving, HH; Rossing, K, 2002) |
| "Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system." | 2.47 | Differential clinical profile of candesartan compared to other angiotensin receptor blockers. ( Cernes, R; Mashavi, M; Zimlichman, R, 2011) |
| " RI was compared to the ARB, candesartan (3 mg/kg/day PO), and to the ACEI, enalapril (60 mg/kg/day PO) in a 4-week dosing paradigm." | 1.35 | A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. ( Carlson, T; Kowala, MC; Leadley, R; Major, TC; Okerberg, C; Olszewski, B; Ostroski, R; Rosebury, W; Schroeder, R, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, K | 2 |
| Sasamura, H | 1 |
| Nakamura, M | 1 |
| Sakamaki, Y | 1 |
| Azegami, T | 1 |
| Oguchi, H | 1 |
| Tokuyama, H | 1 |
| Wakino, S | 1 |
| Itoh, H | 1 |
| Major, TC | 1 |
| Olszewski, B | 1 |
| Rosebury, W | 1 |
| Okerberg, C | 1 |
| Carlson, T | 1 |
| Ostroski, R | 1 |
| Schroeder, R | 1 |
| Kowala, MC | 1 |
| Leadley, R | 1 |
| Ketelhut, R | 1 |
| Bramlage, P | 1 |
| Cernes, R | 1 |
| Mashavi, M | 1 |
| Zimlichman, R | 1 |
| Murayama, S | 1 |
| Hirano, T | 1 |
| Sakaue, T | 1 |
| Okada, K | 1 |
| Ikejiri, R | 1 |
| Adachi, M | 1 |
| Kakizawa, H | 1 |
| Itoh, Y | 1 |
| Imamura, S | 1 |
| Matsumoto, T | 1 |
| Ishiwata, Y | 1 |
| Ono, Y | 1 |
| Yamamoto, K | 1 |
| Kato, T | 1 |
| Hayakawa, N | 1 |
| Oda, N | 1 |
| Goto, Y | 2 |
| Nagasaka, A | 1 |
| Senda, T | 1 |
| Itoh, M | 1 |
| Rosei, EA | 1 |
| Rizzoni, D | 1 |
| Muiesan, ML | 1 |
| Sleiman, I | 1 |
| Salvetti, M | 1 |
| Monteduro, C | 1 |
| Porteri, E | 1 |
| Hasebe, N | 1 |
| Kikuchi, K | 1 |
| Kim, S | 1 |
| Ohta, K | 1 |
| Hamaguchi, A | 1 |
| Omura, T | 1 |
| Yukimura, T | 1 |
| Miura, K | 1 |
| Inada, Y | 1 |
| Wada, T | 1 |
| Ishimura, Y | 2 |
| Chatani, F | 1 |
| Kohara, K | 1 |
| Mikami, H | 1 |
| Okuda, N | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Obata, J | 1 |
| Nakamura, T | 2 |
| Kuroyanagi, R | 1 |
| Yoshida, Y | 1 |
| Guo, DF | 1 |
| Inagami, T | 1 |
| Casellas, D | 1 |
| Benahmed, S | 1 |
| Artuso, A | 1 |
| Jover, B | 1 |
| Ushiyama, C | 1 |
| Suzuki, S | 1 |
| Shimada, N | 1 |
| Sekizuka, K | 1 |
| Ebihara, I | 1 |
| Takahashi, Y | 1 |
| Tanaka, A | 1 |
| Koide, H | 1 |
| Rossing, K | 1 |
| Christensen, PK | 1 |
| Jensen, BR | 1 |
| Parving, HH | 1 |
| Matsuo, T | 1 |
| Ishikawa, E | 1 |
| Ohta, M | 1 |
| Shibouta, Y | 1 |
| Imura, Y | 1 |
| Sugiyama, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan cilexetil and Albuminuria
| Article | Year |
|---|---|
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Biphenyl Compounds; | 2011 |
6 trials available for candesartan cilexetil and Albuminuria
| Article | Year |
|---|---|
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diab | 2010 |
Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2003 |
Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2005 |
Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Benzimidazoles; Bi | 2005 |
Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2000 |
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
8 other studies available for candesartan cilexetil and Albuminuria
| Article | Year |
|---|---|
Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2015 |
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
Topics: Administration, Oral; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2008 |
Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2004 |
Renal protective effect of TCV-116 in stroke-prone spontaneously hypertensive rats.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Ben | 1994 |
Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat.
Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzi | 1993 |
Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; | 1997 |
Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Bip | 1999 |
Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Be | 2002 |